IVF cost in the UK varies more than most procedures: the NHS funds limited cycles within NICE NG257 criteria but Integrated Care Board policy varies sharply by region and age, UK private IVF starts around £4,500 per cycle and rises to £9,500 or more once ICSI and pre-implantation genetic testing are added, and patients facing long ICB waits or falling outside the NICE criteria frequently consider a coordinated international pathway. This guide explains what the NHS actually funds under NICE NG257 and HFEA regulation, what UK private fees include, and where the ATDERA Care Network's UK-incorporated Turkey pathway sits in the picture.
The NHS IVF conversation is fundamentally about eligibility windows: age, BMI, prior children, lifestyle factors, and the cycle quota the receiving Integrated Care Board has chosen to fund within (or outside) the NICE NG257 recommendation. NICE recommends a national standard; ICB implementation varies sharply, and many ICBs fund fewer cycles than the NICE recommendation.
NICE NG257 recommends up to three full cycles of IVF for women under 40 who have been trying to conceive for two years or have an unexplained infertility diagnosis. Many ICBs fund only one or two cycles in practice; the patient's local ICB policy determines actual access.
NICE NG257 recommends one full cycle for women aged 40 to 41 who have not had IVF previously, have no evidence of low ovarian reserve, and have had the implications of IVF at this age clinically explained. Eligibility ends on the 42nd birthday. Many ICBs decline to fund this band entirely.
NHS IVF is not funded from the 42nd birthday onward under any standard ICB policy (NICE NG257 access criteria). Patients aged 42 and over seeking IVF are directed to UK private routes or a coordinated international pathway. Live birth rates above 42 are also materially lower (see the success-rate section below); pathway counselling matters as much as access.
Even where the NICE clinical criteria are met, NHS IVF availability varies sharply by Integrated Care Board. Some ICBs fund three cycles per the NICE recommendation; others fund one cycle only; a small number fund none for the 40-to-41 band. Waiting times can be six to eighteen months or longer in regions with restricted commissioning. The patient's GP or local fertility clinic confirms the applicable ICB policy.
Most ICBs require a BMI between 19 and 30 for NHS-funded IVF and ask both partners to be non-smoking for at least three to six months before treatment. Some ICBs add a no-living-children-from-the-current-or-any-prior-relationship criterion. Lifestyle optimisation is part of the standard clinical pathway and improves cycle outcomes regardless of funding source.
HFEA's 2024 policy update broadened the eligibility intent so that same-sex couples and single women would not be required to self-fund initial fertility investigations before NHS-funded treatment was considered. ICB implementation of this update is uneven; many ICBs still apply the prior funding-history criterion in practice.
Criteria summarised from NICE clinical guideline NG257 (Fertility: assessment and treatment, March 2026 — which replaced CG156) and HFEA national IVF data. Individual eligibility is determined by the patient's GP referral and the receiving NHS fertility service; ICB-level commissioning policy is the binding constraint.
UK private IVF fees fall into reasonably well-defined bands by cycle type. The ranges below describe the established UK private fertility-clinic market — Care Fertility, CRGH, Bourn Hall, IVI London, Newlife, and the major regional networks. Premium central London cohorts (Harley Street tier) typically add £1,500 to £3,000 across each band. The fees below are per cycle; cumulative costs across multiple cycles are not represented.
| Treatment | UK private benchmark | ATDERA Care Network — Turkey | In-country duration |
|---|---|---|---|
| Standard IVF (no ICSI, no PGT-A) | £4,500–6,500 | £2,200–3,200 | 12–16 days |
| IVF + ICSI (intracytoplasmic sperm injection) | £5,500–7,500 | £2,800–3,800 | 12–16 days |
| IVF + PGT-A (pre-implantation genetic testing) | £7,000–9,500 | £3,800–5,000 | 14–18 days |
| Frozen embryo transfer (FET) | £1,200–2,800 | £700–1,200 | 5–8 days |
What is typically included in a UK private IVF cycle fee:
What is typically not included:
UK private IVF cycle fees range £4,500–£6,500 for standard IVF, £5,500–£7,500 with ICSI, and £7,000–£9,500 with PGT-A genetic testing (CRGH London anchors the budget end at £3,995 standard IVF; Care Fertility, Bourn Hall, and IVI London occupy the established mid-market). UK private fees vary by a factor of two or more across clinics for what looks superficially like the same procedure, and the drivers are clinical and operational rather than arbitrary. Patients deserve to understand what they are paying for rather than a price-anchored 'X is better' framing — the six drivers below describe the real differences between a high-volume HFEA-inspected centre with a senior embryologist and a budget-tier clinic running a generic protocol on a younger lab.
IVF outcomes correlate strongly with embryologist case volume. Clinics with senior embryologists, dedicated andrologists, and high annual cycle volumes carry a different cost base from low-volume clinics, and the technical-outcome-stability differential is real. Lab accreditation status (HFEA inspection rating) is a public signal worth checking before committing.
Time-lapse incubation systems, single-step culture media, and dedicated vitrification protocols carry capital cost that flows through to the cycle fee. Whether these technologies materially improve live birth rates for any individual patient depends on the clinical indication; the equipment is not a universal benefit, but it is a legitimate cost driver where indicated.
IVF clinicians vary in sub-specialty: ovulation induction, advanced maternal age management, recurrent implantation failure, PGT-A interpretation, and complex donor pathways. A clinic that matches the patient's clinical profile to a sub-specialist consultant charges more than one that operates a generic protocol; for complex cases the matching matters more than the headline fee.
PGT-A (aneuploidy screening) and PGT-M (single-gene disorder screening) are separate clinical decisions per cycle. Day-3 vs day-5 vs day-6 trophectoderm biopsy, frozen-vs-fresh transfer protocol, and the laboratory's NGS interpretation pipeline all affect both cost and outcome. The decision to add PGT-A is patient-specific, not a default.
Donor egg and donor sperm programmes operate under HFEA regulation in the UK; donor identity disclosure to the resulting child at age 18 is mandatory. International donor programmes operate under different regulatory frameworks; the donor-sourcing chain documentation is part of the cost question and not a separate question. Programmes that cannot document their donor sourcing chain warrant scrutiny.
A clinic offering one post-test consultation charges a different fee from one offering structured follow-up at beta-hCG, six-week ultrasound, twelve-week scan handoff to NHS antenatal care, and live birth outcome reporting integrated with HFEA national data. The cadence is a clinical value, not a marketing add-on, and the fee reflects it.
HFEA preliminary 2022 data places live birth rate per embryo transferred at approximately 35% for women under 35, falling to 26% at 35–37, 18% at 38–39, 10% at 40–42, and 5% at 43–44 (own-egg cycles, UK private and NHS combined). NICE NG257 access criteria (March 2026, replacing CG156) limit NHS-funded IVF to women under 42.
IVF outcomes are age-dependent, and the figures below summarise published HFEA national age-banded birth rates per embryo transferred — HFEA's primary published metric. Per-started-cycle rates are typically lower because not every cycle reaches transfer (freeze-all protocols, OHSS deferrals, lab-stage attrition). Cumulative cycle live birth rates across two or three cycles are higher and more clinically informative than single-cycle figures.
Clinics publishing headline success rates without an age band, without specifying the denominator, or without separating own-egg from donor-egg cycles are presenting an unreliable summary.
approximately 35% per embryo transferred
The highest age band; cumulative across three cycles approaches 60% in well-selected patients.
approximately 26% per embryo transferred
A modest but clinically meaningful step down from the under-35 band.
approximately 18% per embryo transferred
The decline accelerates from this band onward; cumulative cycle counselling becomes important.
approximately 10% per embryo transferred
NHS funding ends within this band per most ICB policies; donor-egg conversation often opens here.
approximately 5% per embryo transferred
Own-egg success rates fall sharply; donor-egg cycles produce materially higher live birth rates and warrant explicit clinical conversation.
approximately 2% or below per embryo transferred (own egg)
Donor-egg pathway is the primary clinical option above 44.
Source: HFEA preliminary 2022 fertility-treatment dataset (published 2024), reported per embryo transferred. The HFEA notes that birth rates per embryo transferred have not yet been fully validated for the 2019–2022 reporting cycle and asks readers not to compare these figures to other reports until validation is complete; the figures here are read as illustrative ranges rather than as a clinic-comparison standard. The ATDERA Care Network commits to publishing partner-facility live birth rates per age band per ATDERA Care Network reporting protocol once the IVF clinician roster is in place.
ATDERA is UK-incorporated (ATDERA GLOBAL LIMITED, Companies House 17173428) and coordinates IVF exclusively at JCI-accredited partner facilities, university medical centres, and established teaching hospitals in Turkey. The structural cost differential between UK private and the ATDERA pathway reflects a lower clinic and lab cost base in Turkey at HFEA-equivalent regulated centres — not a compromise on embryologist seniority, regulatory compliance, or aftercare. The ATDERA investment range is the case-specific written-estimate range issued after the pre-consultation enquiry; the actual figure is itemised line-by-line and finalised in writing before any travel commitment is taken.
UK private clinics rightly criticise the brokerage-model end of the international IVF market. Aggregator pricing, foreign-incorporated brokers, leisure-led marketing, headline success-rate claims without age-band data, and absent donor-sourcing transparency are real and documented patterns — and bundled headline pricing without itemised line items is the most reliable signal that you are looking at the brokerage model rather than a coordinated clinical pathway. The comparison below sets out the structural differences between that baseline and how the ATDERA Care Network is configured. The differences are matters of organisational record, not marketing claims.
| UK clinic concern | Generic Turkey clinic | ATDERA model |
|---|---|---|
| Foreign jurisdiction with limited recourse if outcomes disappoint | Foreign-incorporated clinic, no UK regulatory presence | UK-incorporated (ATDERA GLOBAL LIMITED, Companies House 17173428); ICO-registered patient-data handling |
| Anonymous aggregator listings with no verified clinician accountability | Broker model; clinician revealed only after a deposit | Verified clinicians with verifiable credentials and written permission to publish; ATDERA Care Network roster |
| Discount-led positioning raises clinical-compromise questions | Leads with price-comparison claims and bundled packages | Evaluation-first model. Transparent expenditure ranges sourced to BDA 2024. No promotional framing. |
| Unclear or absent facility accreditation | Standalone clinics; accreditation status not disclosed | Treatment delivered at JCI-accredited facilities, university medical centres, leading teaching hospitals |
| No defined follow-up pathway once the patient is back home | Hand-off ends at the airport; UK-side aftercare uncoordinated | ATDERA Care Network coordinates the full pathway including UK-side follow-up |
| Travel-and-leisure framing positions medical care as a vacation product | Leads with leisure narrative and spa-style imagery | Clinical-education positioning. Same clinical bar as UK private practice. |
| Live birth rate transparency | Headline "success rate" without an age band, often unsourced and conflating own-egg with donor-egg cycles | Live birth rates published per age band (under 35 / 35–37 / 38–40 / over 40) per ATDERA Care Network reporting protocol, separating own-egg from donor-egg cycles in HFEA-comparable framing |
| Genetic testing protocol disclosure | PGT-A bundled into the headline cycle fee or excluded without disclosure; biopsy timing and laboratory pipeline not documented | PGT-A and PGT-M listed as discrete line items on every estimate; opt-in per patient case with documented biopsy timing and NGS interpretation pipeline |
| Donor egg / sperm regulatory framework | Variable transparency on donor sourcing; donor identity disclosure obligations to the resulting child not always specified | Compliance with HFEA-equivalent partner-facility framework; donor screening, gamete handling, legal parentage, and donor-sourcing chain documented in writing before any commitment is taken |
The article would be incomplete without a clear contraindication list. Patients in one of the categories below should not start an IVF cycle yet — in Turkey, in the UK private system, or anywhere else. Bringing this up here, before the enquiry form, is a deliberate choice: we lose the inappropriate cohort gracefully and build trust with the appropriate one. Most of the categories below are time-limited rather than permanent — a delay-and-optimise pathway often produces a better cumulative outcome than a rushed cycle.
The published data shows materially lower live birth rates outside this band, and most regulated clinics decline to start a cycle until the patient is within range. A weight-optimisation pathway with a registered dietitian over six to twelve months frequently produces a better cumulative outcome than an immediate cycle outside the band.
Endometriosis, fibroids, hydrosalpinx, and severe PCOS often warrant the corrective procedure first and the IVF cycle second. The clinical sequence is sequential, not parallel. A diagnostic workup before the IVF cycle is part of the standard pathway.
Cessation typically required for both partners three to six months before any cycle commitment, for both clinical and consent reasons. Both ovarian reserve and sperm parameters respond meaningfully to lifestyle change within this window.
A urology / andrology workup before the IVF cycle outperforms an immediate cycle in many cases. Treatable causes (varicocele, infection, hormonal imbalance) may be addressed before committing to ICSI; in cases where ICSI is the right pathway regardless, the workup informs the prognosis honestly.
IVF is emotionally intense. Structured psychological readiness assessment — recommended by HFEA, noted by NICE — is part of the standard pathway. Active untreated mood disorder, eating-disorder relapse, or a current substance-misuse episode warrants stabilisation first.
No clinic, in any jurisdiction, can deliver an outcome that the age-banded HFEA data does not support for the patient's specific clinical profile. Cumulative-cycle counselling is the appropriate response, not a more permissive provider. A clinic that promises an outcome materially above the age-band national average warrants scepticism.
Where AMH and antral follicle count both indicate severely diminished ovarian reserve, an own-egg cycle commitment without an explicit donor-egg conversation is incomplete clinical practice. The patient deserves to hear both options, with honest age-banded prognosis figures, before committing to a route.
ATDERA GLOBAL LIMITED (Companies House #17173428, registered in England and Wales) is a UK-registered international healthcare coordination organisation; see the About ATDERA page for the registered structure and the Specialists page for verified partner clinicians. Care is delivered through the ATDERA Care Network of partner facilities in Turkey, and the standard medical disclaimer applies to the clinical content above. See also ATDERA’s other UK cost-pillar guides: dental, rhinoplasty, laser eye surgery, bariatric, orthopedic, and rectus diastasis cost guide. The information on this page is intended as an honest engagement with the published UK IVF cost picture and the age-banded live birth rate evidence; it is not a substitute for personal clinical advice or a substitute for the case-specific written estimate ATDERA issues after the pre-consultation enquiry. NICE NG257 access criteria, HFEA preliminary 2022 age-banded birth rate figures, and CRGH/Care Fertility benchmark prices were verified against their published sources on 2026-05-08.
Each case is reviewed by a verified partner reproductive-medicine specialist at a JCI-accredited or university-medical-centre partner facility before any travel commitment is taken. ATDERA returns an itemised written estimate after the case review, with each cost component listed as a separate line item rather than a bundled headline figure.
